Business
Grant of Incentive Options over Stock
Cardiogeni PLC has granted incentive options over shares to its Executive Chairman, Dr. Darrin M Disley OBE, and Chief Scientific Officer, Sir Martin Evans, with each receiving 750,000 options, while Non-Executive Directors Mr. Chaim Hurvitz, Professor Joanne Martin, and Lord James Bethell each received 250,000 options. These options, granted on June 26, 2026, have a three-year vesting period and a nil exercise price, and are part of an unapproved incentive option plan. Following these grants, the company has 2,250,000 options and 2,560,396 warrants outstanding. Disclaimer*
About this update from Cardiogeni Plc
29 June 2026 Cardiogeni PLC ("Cardiogeni", "CGNI" or the "Company") Grant of Incentive Options over Stock Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines, today announces that pursuant to the authorities granted to it by shareholder resolutions passed at the Annual General Meeting held on December 31 2025 that it has granted certain Executive and Non-Executive Directors with incentive options over shares according to the below schedule. Name Role Grant Date Vesting Period / Price Number of Options Granted Total Number of Options Held Dr Darrin M Disley OBE Executive Chairman 26/06/26 3 years / Nil 750,000 750,000 Sir Martin Evans CSO 26/06/26 3 years / Nil 750,000 750,000 Mr Chaim Hurvitz NED 26/06/26 3 years / Nil 250,000 250,000 Professor Joanne Martin NED 26/06/26 3 years / Nil 250,000 250,000 Lord James Bethell NED 26/06/26 3 years / Nil 250,000 250,000 The incentive options have been issued under an unapproved incentive option plan so do not beneft from from the tax advantaged status of a HMRC approved Enterprise Management Incentive plan. Following this grant, there are 2,250,000 options outstading and 2,560,396 warrants oustading. ENDS The directors of Cardiogeni accept responsibility for this announcement. For further information please contact: Cardiogeni PLC Dr Darrin M Disley, Executive Chairman Ajan Reginald, Executive Officer Via First Sentinel First Sentinel Corporate Finance Limited, Corporate Adviser Brian Stockbridge +44 (0) 7858 888007 SP Angel Corporate Finance LLP, Corporate Broker David Hignell Vadim Alexandre Devik Mehta +44 20 3470 0470 About Cardiogeni Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a specific therapeutic function. The Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor Sir Martin Evans and the pl...